SSY GROUP (02005) has obtained the drug manufacturing registration approval from the National Medical Products Administration for Levofloxacin Drops (0.488% (5ml: 24.4mg)).

SSY Group (02005) announces that the group has obtained the drug production registration certificate for levofloxacin eye drops (0.488% (5ml: 24.4mg)) from the China National Medical Products Administration (NMPA), which belongs to the category 4 chemical drugs and is considered to have passed consistency evaluation. Levofloxacin eye drops are mainly used to treat blepharitis, meibomian gland inflammation, lacrimal sac inflammation, conjunctivitis, hordeolum, keratitis, as well as for sterile therapy in ophthalmic perioperative period. This approval enriches the variety of ophthalmic preparations of the group. The Board of Directors is pleased to announce that the group has also obtained NMPA's approval for compound pico sodium sulfate granules (each bag containing 10mg of pico sodium sulfate), which belongs to the category 3 chemical drugs and is considered to have passed consistency evaluation. Compound pico sodium sulfate granules are mainly used for colonoscopy and X-ray examination preparation, and can also be used to clean the intestines before surgery. As announced on December 4, 2025, the pico sodium sulfate active pharmaceutical ingredient of the group has been registered and approved by NMPA to be used as a raw material in marketed preparations.